Another approach for the same problem is using PPARα/δ dual agonists, such as GFT505, which have been shown to treat type 2 diabetes while altogether avoiding the cardiovascular risk of PPARγ agonists (186). The gene discussed is PPARG; the disease is type 2 diabetes mellitus.